<DOC>
	<DOCNO>NCT00005800</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness doxorubicin docetaxel treat woman stage III breast cancer .</brief_summary>
	<brief_title>Doxorubicin Docetaxel Treating Women With Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate clinical pathological response rate sequential doxorubicin docetaxel chemotherapy neoadjuvant treatment woman stage III breast cancer . - Measure signal transducer activator transcription ( STAT ) activation neoadjuvant chemotherapy regimen patient population . - Correlate response chemotherapy STAT activation neoadjuvant chemotherapy regimen patient . - Determine potential predictor response correlate STAT activation measure Bcl-2 , Bcl-xL , Bax protein level , tyrosine kinase level , growth rate tumor , apoptotic index neoadjuvant chemotherapy regimen patient . - Correlate response chemotherapy level STAT activation association presence Bcl-2 proteins tyrosine kinase , growth rate tumor , apoptotic index patient . - Evaluate toxicity neoadjuvant chemotherapy regimen give dose-dense fashion patient . OUTLINE : Patients receive doxorubicin IV day 1 every 2 week 3 course . After 3 week rest , patient receive docetaxel IV 1 hour day 1 every 2 week 3 course . Filgrastim ( G-CSF ) administer subcutaneously day 3-10 doxorubicin docetaxel course . Within 6 week completion neoadjuvant chemotherapy , patient undergo surgery mastectomy lumpectomy axillary lymph node dissection . PROJECTED ACCRUAL : A total 45 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically pathologically confirm stage III breast cancer Clinical evidence primary invasive breast tumor great 5 cm dimension ( T3 ) evidence metastatic disease clinically stag study include compute tomography ( CT ) scan chest , abdomen , pelvis , bone scan Inflammatory breast carcinoma define diffuse brawny induration skin breast erysipeloid edge due embolization dermal lymphatics pathologic evidence dermal lymphatic invasion No bilateral breast cancer unless synchronous Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 70 Sex : Female Menopausal status : Not specify Performance status : Eastern Cooperative Oncology Group ( ECOG ) 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL SGOT/SGPT le 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 4 time ULN provide SGOT/SGPT great ULN Renal : Creatinine great 1.5 mg/dL Cardiovascular : If prior cardiac event ischemia electrocardiogram , must clear cardiologist LVEF least 50 % rest MUGA No severe cardiac dysfunction No prior concurrent angina pectoris , congestive heart failure , major ventricular arrhythmia No uncontrolled essential hypertension Other : Not pregnant nursing Fertile patient must use effective nonhormonal barrier contraception No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , intraductal lobular carcinoma situ breast No serious medical psychiatric illness would preclude study consent treatment No prior severe intolerable reaction filgrastim ( GCSF ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy breast Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>